Peri-operative chemotherapy with or without bevacizumab in operable oesophagogastric adenocarcinoma

Lancet Oncol. 2017 May;18(5):e243. doi: 10.1016/S1470-2045(17)30280-2.

Authors

Geoffrey Ku¹, David Ilson²

Affiliations

¹ Department of Medicine, Memorial Sloan Kettering Cancer Center, Gastrointestinal Oncology Service, New York, NY 10065, USA. Electronic address: [email protected].
² Department of Medicine, Memorial Sloan Kettering Cancer Center, Gastrointestinal Oncology Service, New York, NY 10065, USA.

PMID: 28495288
DOI: 10.1016/S1470-2045(17)30280-2

No abstract available

Publication types

Letter
Comment

MeSH terms

Adenocarcinoma*
Antineoplastic Combined Chemotherapy Protocols
Bevacizumab*
Esophageal Neoplasms
Esophagogastric Junction
Humans

Substances

Bevacizumab